http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005519848-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2001-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2005519848-A |
| titleOfInvention | Small molecule composition for binding to HSP90 |
| abstract | Structural differences in the binding pockets of members of the HSP90 family are due to the use of designed small molecules that interact with the N-terminal binding pocket with an affinity higher than ADP and different from ansamycin antibiotics for at least one HSP90 family Can be utilized to achieve differential degradation of kinases and other signaling proteins. In addition, these small molecules can be designed to be soluble in aqueous media, thus providing further advantages over the use of ansamycin antibiotics. Pharmaceutical compositions containing a pharmaceutically acceptable carrier and a small molecule comprising a binding moiety that binds to the N-terminal pocket of at least one member of the HSP90 family of proteins can be formulated. Such binding moieties have been found to have anti-proliferative activity against tumor cells that depend on proteins that require the HSP90 chaperone for function. However, different chemical species have different activities, allowing selection of Her2 degradation without degradation of Raf kinase, for example. Thus, the binding moiety possesses unique targeting capabilities. In addition, small molecules can be linked to targeting moieties to provide targeting of activity against specific types of cells. Accordingly, the present invention further provides a method for treating diseases including cancer by administration of these compositions. A dimeric form of the binding moiety may be used. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009542716-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010522184-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016028063-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011503206-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013177389-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015143698-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10336757-B2 |
| priorityDate | 2000-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 262.